All new submissions to the IRB should be made via https://stfrancis.imedris.net. Prior to submission, all study staff must review the training videos (internal users only) found on the IRB website prior to requesting or making a submission into iRIS.
New Investigators and study staff MUST complete training in the protection of human research subjects prior to receiving IRB approval of a protocol. Training information and materials may be obtained by contacting the IRB office or reading the Training of Investigators and Study Staff topic page.
Find the IRB instructions here.
The IRB offers four different consent form templates for each category of research with the exception of retrospective record reviews. Their use is required.
- Template 1: Interventional studies involving drug or devices
- Template 2: Social or behavioral research studies
- Template 3: Establishment of a research registry or database
- Template 4: Case reports, case series, or prospective record review
Please note that approval may be delayed if elements of the application submission package are missing or incomplete. An application submission package consists of the following:
- Application*: A
new study should be submitted electronically via https://stfrancs.imedris.net and signed
off by the Principal Investigator. Saint Francis Hospital and Medical Center
policy does not allow for students, residents, or trainees to act as Principal
Investigators; these individuals will need to find a qualified member of the
Medical, Dental, or Nursing staff to act as the Principal Investigator. There
are two applications forms, please complete the appropriate form. One form is for
Full Board Review and one form is for Expedited and Exempt Review. If you have
any questions as to whether your study will qualify for full board, expedited,
or exempt review, please contact the IRB office for guidance before completing
the application. If you are
unsure if your project constitutes as human subject research, please complete
and submit the Human Subject Research Determination Form found on iRIS and
short protocol describing your project. Determinations are to be made by the
IRB Chair. Written documentation of the determination will be provided.
- Consent document: If applicable, a document that is appropriate to the proposed research and is written in simple, non-technical language that can be easily understood by the prospective subjects.
- Sponsor sample/template consent: If applicable, provide the sponsor sample/template consent document which was used to develop the final consent document. Language and information revisions regarding risks, procedures, and other elements of consent need to be justified in writing. Minimal clarification and simplification of language and information does not constitute the need to justify changes in writing.
- Protocol*: The document may be written in technical language which provides a complete description of the proposed research and procedures. A protocol must be submitted for all research studies requiring IRB approval.
If the sponsor has provided a sample/template protocol for use in developing the final site specific protocol, language and information revisions regarding risks and procedures (e.g. participation in only one arm of the study versus all arms) need to be justified in writing. Minimal clarification and simplification of language and information does not constitute the need to justify changes in writing.
- Investigator's Brochure: If applicable, the investigator's brochure, including data on previous animal and human experience associated with the investigational article, must be submitted with the application. This applies to interventional research involving drug or device protocols.
- Assessment materials: The IRB must review and approve all documents which the subject will encounter during study participation and/or any formal data collection forms which will be used in a study. These documents include, but are not limited to questionnaires, interview/survey forms, experiment session outlines, instructional sheets, and focus group discussion outlines.
- Advertisement(s) for subject recruitment: If applicable, all advertisements used for subject recruitment need IRB approval prior to their use. Guidelines for advertisements are included in the IRB application instructions.
- Form 1571 and Form 1572: If the study will be conducted by a sponsor under an investigational new drug (IND) or investigational device exemption (IDE), a FDA form 1571 and form 1572 for the principal investigator must be included with the application. Please submit one copy of each document.
- Research Contract*: If the study will be funded and conducted by a sponsor, a copy of the fully executable sponsor-investigator contract/agreement must be included with the application. The contract must be submitted to the Department of Legal Services for review and approval prior to receiving IRB approval.
- Curriculum vitae: A CV or resume for each investigator listed on the application must be provided if a copy is not already on file with the IRB. Investigators may submit a CV/resume with each new submission to ensure that the most current copy of the document is on file with the IRB. Please submit one copy for each investigator listed.
- Financial Disclosure and Conflict of Interest form: A Financial Disclosure and Conflict of Interest form for each investigator listed on the application must be completed. Please note that section A is for individuals who do not have a conflict of financial interest to disclose; section B is for individuals who have a conflict or financial interest to disclose. Section B must be completed if the investigator has involvement in the study design, implementation, and data collection. Please submit one copy for each investigator listed and complete EITHER section A or B, not both.
- Unaffiliated Investigator Agreement (UIA): If applicable, an UIA for each investigator who is not affiliated with St. Francis Hospital and Medical Center must be completed and submitted with the application. Affiliation with St. Francis Hospital and Medical Center includes members of the Medical, Dental or Nursing staff, Woodland Physicians and Asylum Hill Family Medicine Associates. UIAs need to be submitted directly to the IRB office and not to the Signatory Official listed on the document. Please submit one copy for each investigator listed to which this applies.
- Training documentation: All investigators and research staff must provide documentation of training in the protection of human research subjects if a copy is not already on file with the IRB. Training information and materials may be obtained by contacting the IRB office or reading the Training of Investigators and Study Staff topic page. Please submit one copy for each investigator listed.
*For studies which involve the use of investigational drugs:
Investigational drugs must be stored in the hospital Pharmacy unless the investigator ensures that storage, dispensing, accountability, and security comply with institutional policy and federal and state laws. The Director of Pharmacy, or delegated pharmacy staff, must approve plans for control of investigational drugs maintained outside of the pharmacy. Investigators who choose to store investigational drugs outside the Pharmacy will be subject to regular auditing by the Pharmacy.
Drug costs, when applicable, and other Pharmacy expenses associated with the study will be charged to the investigator and must be properly allocated for in the research contract or study budget and reimbursed to the Pharmacy. A department budget or special fund account will need to be provided to the Pharmacy from which the following fees will be drawn:
- Study initiation (one time fee)
- Randomization (per subject enrolled)
- Drug preparation and dispensing (per dose)
- Drug cost (for non-sponsored studies)
- Inventory and record keeping (monthly fee which includes quality assurance measures, monitor site visits, and drug storage)
- Study closure (one time fee which includes destruction of remaining drug, copying and archiving study related information)
Please note that even if the Pharmacy is not storing or dispensing study drugs study initiation fees will be charged to cover the costs of protocol review and to ensure that drugs not handled by the Pharmacy are in accordance with regulatory standards.
Please contact the Director of Pharmacy at (860) 714-7983 for further information.